Eupraxia Pharmaceuticals EPRX
NASDAQ EPRX
$8.06 +0.43 (+5.64%)
At close: Nov 11, 2026 · 4:00 PM EST

Eupraxia Pharmaceuticals (EPRX) Net Margin (2024 - 2025)

Updated

Eupraxia Pharmaceuticals (EPRX) recorded Net Margin of -1881.16% in Q1 2025, down 1167.47 percentage points from -713.70% a year earlier.

Analysis

Eupraxia Pharmaceuticals (EPRX) Net Margin (2024 - 2025) Analysis & Trends

For FY2024, Eupraxia Pharmaceuticals reported Net Margin of -3880.76%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 26.44%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 0.83%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 24.24%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 28.01%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 20.69%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 37.28%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 29.27%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 19.55%
10 Eupraxia Pharmaceuticals 304.87 Mn -174.66 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 -1,881.16%
Mar 31, 2024 -713.70%
API Access

Eupraxia Pharmaceuticals Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=EPRX&period=max&api_key=YOUR_API_KEY